Caplin Point Laboratories (CAPLIPOINT) Fundamentals 2026 — P/E 29.4x, Revenue Analysis | SniperIQ
Caplin Point Laboratories (CAPLIPOINT) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹18,855 Crore, trading at ₹2480.95 on the BSE. This SniperIQ fundamentals page covers Caplin Point Laboratories's valuation (P/E 29.4x, P/B 5.3x), profitability (net margin 29.3%), revenue (₹2,187 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Caplin Point Laboratories's market cap?
Caplin Point Laboratories (CAPLIPOINT) has a market capitalization of approximately ₹18,855 Crore, trading at ₹2480.95 on the BSE. Market cap moves with the live share price.
What is Caplin Point Laboratories's P/E ratio?
Caplin Point Laboratories's trailing twelve-month P/E ratio is 29.4x, with a price-to-book (P/B) of 5.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Caplin Point Laboratories?
Caplin Point Laboratories runs a net profit margin of 29.3%, a gross margin of 51.0%, and an operating margin of 35.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Caplin Point Laboratories generate?
Caplin Point Laboratories reported revenue of ₹2,187 Crore for fiscal year 2026, with net income of ₹641 Crore and earnings per share (EPS) of 84.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Caplin Point Laboratories pay a dividend?
Caplin Point Laboratories offers a trailing dividend yield of about 0.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Caplin Point Laboratories financially healthy?
Caplin Point Laboratories carries a debt-to-equity ratio of 0.00x and a current ratio of 6.70x, with a market beta of 0.19. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Caplin Point Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Caplin Point Laboratories (CAPLIPOINT) the key facts are: market cap ₹18,855 Crore, P/E 29.4x, revenue ₹2,187 Crore, 52-week range 1502.45-2700. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Caplin Point Laboratories's full fundamentals live
Get Caplin Point Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.